Howson adds 2 more central nerve heavy drugs! Paliquinone slow release tablets in china's first imitation.

On June 19, two new drugs for central nervous disease sashimi were approved by Howson Pharmaceuticals, respectively, paliquinone relief tablets and oxaen flat-mouth collapse tablets, and two new drugs were declared in accordance with the new 4 categories, and were approved as if they were consistently evaluatedAmong them, paliquinone slow release tablets for the first imitation in Chinapaliquinone slow release tablet
paliquinone is the main metabolite of libido, compared to libido, paliquinone is more effective, more safe, and better patient complianceParidosterone and lipasterone were developed by Johnson and Johnson and were atypical antipsychotic drugs, which reduced the side effects of patientconorins compared to typical antipsychotic drugsHaussen submitted an application for listing of paliquina probation tablets in March 2019, Ishiguro Group submitted its second application for listing of the drug in December 2019, and produced the same production line in paragraph 5 of the priority review scope (i) and has passed the FDA pre-approval inspection to apply for domestic listing of generic drugs into the priority review processin addition, the palmic acid Paliketone injection liquid generics developed by Howson are also in the clinical development stageThe drug, also developed by Johnson and Johnson, generated sales of $3.33 billion in 2019Source: PharmaGoO'Nina Flat SpoutClinically Used in the treatment of schizophrenia, manic episodes and bipolar disorderO nitrogen flat sheet for the 4 plus 7 band volume procurement varieties, the domestic market share is mainly occupied by HaussenHaussen's O'Nis flat is also the first in the country, and the first to pass the consistency evaluationThis time, HaussenO nitrogen collapse film was approved for listing, the fourth in the country through the consistency evaluation of the enterpriseIn addition, Howson also laid out the o nitrogen-level oral instant membrane, is currently in the "in the review" stageSource: PharmaGoHaussen's portfolio of central nervous system diseases, including oxamine tablets, agometine tablets, and statintablets In 2019, Howson's central nervous system disease drug portfolio generated revenue of about $2,171 million, or 25 percent of its total revenue So far this year, Howson Pharmaceuticals has submitted a list application for the smoking cessation drug bararic acid valnicin tablets, the second generation of antipsychotic acid rhodicine tablets, and continues to improve its central nervous system disease portfolio.